The STRIDE Study: Concurrent vs Sequential Enzalutamide With Sipuleucel-T for mCRPC
Daniel P. Petrylak, MD, discusses the results of the phase II STRIDE study in metastatic castration-resistant prostate cancer (mCRPC).
Clinical Pearls
Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses the results of thephase II STRIDE studyin metastatic castration-resistant prostate cancer (mCRPC).
- The STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for mCRPC.
- There was no difference seen in immune parameters when comparing early and delayed enzalutamide. The prime-boost effect was similar in the two arms.
- Anecdotally, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
